EA Series Trust Strive 500 ETF (NYSE: STRV)

Últimas noticias sobre EA Series Trust Strive 500 ETF (NYSE:STRV)

Technology

Healthcare

Consumer Cyclical

Financial Services

Industrials

Consumer Defensive

Energy

Communication Services

Utilities

Real Estate

Basic Materials

Other

The Fund seeks to track the investment results of the Solactive GBS United States 500 Index (the Index), which is a float-adjusted, capitalization weighted index consisting of equity securities of the 500 largest companies in the U.S. stock market. Securities are first screened for inclusion in the Index Universe. The Index Universe is exclusively comprised of U.S. equity securities, listed on a U.S. exchange, and traded in U.S. Dollars. To determine the Index components (each an Index Component and collectively, the Index Components) all equity securities in the Index Universe are sorted according to total market capitalization in descending order and ranked. The largest 500 securities are then selected as Index Components. Each Index Component is subsequently assigned a weight based on its free float market capitalization. The weight represents the percentage amount of the Index Component as a percentage of the total Index. The Index is calculated as a total return index in U.S. dollars.

Microsoft Corp

Apple Inc

Nvidia Corp.

Amazon.Com Inc

Meta Platforms, Inc.

Alphabet Inc

Eli Lilly & Co.

Broadcom Inc

Jpmorgan Chase & Co.

Strive 500 ETF

KRUZ

NANC

STRV

TSLA

YALL

Algunos ETF temáticos superaron al S&amp;P 500 este año. ¿Qué factores explican sus impresionantes rendimientos? ¡Descúbrelo aquí!

ETF políticos que superan al S&amp;P 500: ¿Cómo logran estos fondos rendimientos superiores?

EA Series Trust Strive 500 ETF

<p>RBC Capital  analyst Douglas Miehm   maintains Knight Therapeutics (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GUD#TSX">GUD</a>) with a Outperform and raises the price target from C$7 to C$8.</p>


News

Price Target

Analyst Ratings

TSX:GUD

RBC Capital Maintains Outperform on Knight Therapeutics, Raises Price Target to C$8

<p>Susquehanna  analyst Shyam Patil   maintains JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) with a Neutral and raises the price target from $35 to $45.</p>


Susquehanna Maintains Neutral on JD.com, Raises Price Target to $45

<p>RBC Capital  analyst Paul Treiber   maintains Enghouse Systems (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ENGH#TSX">ENGH</a>) with a Outperform and lowers the price target from C$40 to C$38.</p>


TSX:ENGH

RBC Capital Maintains Outperform on Enghouse Systems, Lowers Price Target to C$38

<p>Susquehanna  analyst Joseph Stauff   upgrades Boyd Gaming (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>) from Neutral to Positive and lowers the price target from $79 to $77.</p>


Upgrades

Susquehanna Upgrades Boyd Gaming to Positive, Lowers Price Target to $77

<p>High-rolling investors have positioned themselves bullish on Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in VKTX often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 8 options trades for Viking Therapeutics. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 37% bullish and 37% bearish. Among all the options we identified, there was one put, amounting to $25,535, and 7 calls, totaling $353,860.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $15.0 to $77.5 for Viking Therapeutics during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Viking Therapeutics stands at 531.67, with a total volume reaching 1,808.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Viking Therapeutics, situated within the strike price corridor from $15.0 to $77.5, throughout the last 30 days.</p>
<h3>Viking Therapeutics 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741794336_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$9.8</td>
<td>$9.35</td>
<td>$9.6</td>
<td>$25.00</td>
<td>$96.0K</td>
<td>218</td>
<td align="right">101</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/04/25</td>
<td>$3.0</td>
<td>$1.89</td>
<td>$2.8</td>
<td>$30.00</td>
<td>$70.0K</td>
<td>534</td>
<td align="right">18</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$1.4</td>
<td>$0.98</td>
<td>$1.32</td>
<td>$40.00</td>
<td>$44.4K</td>
<td>1.0K</td>
<td align="right">802</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/04/25</td>
<td>$3.9</td>
<td>$2.75</td>
<td>$2.98</td>
<td>$30.00</td>
<td>$44.4K</td>
<td>534</td>
<td align="right">376</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$1.4</td>
<td>$0.97</td>
<td>$1.31</td>
<td>$40.00</td>
<td>$44.1K</td>
<td>1.0K</td>
<td align="right">465</td>
</tr>
</tbody>
</table>
</p>
<h3>About Viking Therapeutics</h3>
<p>Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.</p>
<p>In light of the recent options history for Viking Therapeutics, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Viking Therapeutics's Current Market Status</h3>
<ul>
<li>With a trading volume of 4,579,799, the price of VKTX is up by 8.18%, reaching $28.69.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 42 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Viking Therapeutics</h3>
<p>In the last month, 2 experts released ratings on this stock with an average target price of $102.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Scotiabank has revised its rating downward to Sector Outperform, adjusting the price target to $102.<br />
&#x2A; In a cautious move, an analyst from HC Wainwright &amp; Co. downgraded its rating to Buy, setting a price target of $102. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Viking Therapeutics, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Markets

VKTX

Behind the Scenes of Viking Therapeutics's Latest Options Trends

<p>High-rolling investors have positioned themselves bullish on Cleveland-Cliffs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in CLF often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 9 options trades for Cleveland-Cliffs. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 77% bullish and 11% bearish. Among all the options we identified, there was one put, amounting to $72,828, and 8 calls, totaling $315,324.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $7.0 and $20.0 for Cleveland-Cliffs, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In terms of liquidity and interest, the mean open interest for Cleveland-Cliffs options trades today is 2623.0 with a total volume of 3,496.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Cleveland-Cliffs's big money trades within a strike price range of $7.0 to $20.0 over the last 30 days.</p>
<h3>Cleveland-Cliffs Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741794331_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CLF</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/11/25</td>
<td>$1.0</td>
<td>$0.97</td>
<td>$1.0</td>
<td>$9.50</td>
<td>$100.0K</td>
<td>108</td>
<td>1.0K</td>
</tr>
<tr>
<td>CLF</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$10.45</td>
<td>$10.4</td>
<td>$10.4</td>
<td>$20.00</td>
<td>$72.8K</td>
<td>2.7K</td>
<td>70</td>
</tr>
<tr>
<td>CLF</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$0.42</td>
<td>$0.42</td>
<td>$0.42</td>
<td>$11.00</td>
<td>$42.0K</td>
<td>11.0K</td>
<td>1.3K</td>
</tr>
<tr>
<td>CLF</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$1.21</td>
<td>$1.16</td>
<td>$1.16</td>
<td>$13.00</td>
<td>$32.9K</td>
<td>4.2K</td>
<td>334</td>
</tr>
<tr>
<td>CLF</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$3.1</td>
<td>$3.05</td>
<td>$3.1</td>
<td>$10.00</td>
<td>$31.0K</td>
<td>3.9K</td>
<td>112</td>
</tr>
</tbody>
</table>
</p>
<h3>About Cleveland-Cliffs</h3>
<p>Cleveland-Cliffs Inc is a flat-rolled steel producer and manufacturer of iron ore pellets in North America. It is organized into four operating segments based on differentiated products, Steelmaking, Tubular, Tooling and Stamping and European Operations, but operates through one reportable segment -Steelmaking. It is vertically integrated from mined raw materials, direct reduced iron, and ferrous scrap to primary steelmaking and downstream finishing, stamping, tooling and tubing. It serves a diverse range of other markets due to its comprehensive offering of flat-rolled steel products. Geographically, it operates in the United States, Canada and other countries. The majority of revenue is from the United States. It is a supplier of steel to the automotive industry in North America.</p>
<p>After a thorough review of the options trading surrounding Cleveland-Cliffs, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Cleveland-Cliffs's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 13,423,034, the CLF's price is up by 7.26%, now at $9.68. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 40 days.</li>
</ul>
<h3>What The Experts Say On Cleveland-Cliffs</h3>
<p>2 market experts have recently issued ratings for this stock, with a consensus target price of $13.95.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from GLJ Research persists with their Buy rating on Cleveland-Cliffs, maintaining a target price of $12.<br />
&#x2A; Maintaining their stance, an analyst from Goldman Sachs continues to hold a Buy rating for Cleveland-Cliffs, targeting a price of $15. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Cleveland-Cliffs options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Check Out What Whales Are Doing With CLF

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Hims &amp; Hers Health</strong>.</p>
<p>Looking at options history for Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) we detected 16 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 43% of the investors opened trades with bullish expectations and 37% with bearish.</p>
<p>From the overall spotted trades, 4 are puts, for a total amount of $210,245 and 12, calls, for a total amount of $1,400,840.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $15.0 to $43.0 for Hims &amp; Hers Health over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Hims &amp; Hers Health's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Hims &amp; Hers Health's significant trades, within a strike price range of $15.0 to $43.0, over the past month.</p>
<h3>Hims &amp; Hers Health Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741794326_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$4.45</td>
<td>$4.1</td>
<td>$4.25</td>
<td>$38.00</td>
<td>$501.5K</td>
<td>2.0K</td>
<td>13</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$21.0</td>
<td>$20.7</td>
<td>$21.0</td>
<td>$15.00</td>
<td>$417.9K</td>
<td>3.2K</td>
<td>632</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/14/25</td>
<td>$1.25</td>
<td>$1.17</td>
<td>$1.25</td>
<td>$35.00</td>
<td>$112.3K</td>
<td>935</td>
<td>3.2K</td>
</tr>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$4.15</td>
<td>$4.15</td>
<td>$4.15</td>
<td>$27.00</td>
<td>$104.5K</td>
<td>969</td>
<td>254</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$21.15</td>
<td>$21.0</td>
<td>$21.0</td>
<td>$15.00</td>
<td>$63.0K</td>
<td>3.2K</td>
<td>862</td>
</tr>
</tbody>
</table>
</p>
<h3>About Hims &amp; Hers Health</h3>
<p>Hims &amp; Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.</p>
<p>Following our analysis of the options activities associated with Hims &amp; Hers Health, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is Hims &amp; Hers Health Standing Right Now?</h3>
<ul>
<li>With a trading volume of 11,946,152, the price of HIMS is down by -1.33%, reaching $34.25.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 54 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Hims &amp; Hers Health</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $33.8.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Underperform rating on Hims &amp; Hers Health with a target price of $21.<br />
&#x2A; In a cautious move, an analyst from Morgan Stanley downgraded its rating to Equal-Weight, setting a price target of $60.<br />
&#x2A; Maintaining their stance, an analyst from Leerink Partners continues to hold a Market Perform rating for Hims &amp; Hers Health, targeting a price of $40.<br />
&#x2A; An analyst from B of A Securities downgraded its action to Underperform with a price target of $21.<br />
&#x2A; In a cautious move, an analyst from Citigroup downgraded its rating to Sell, setting a price target of $27. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Hims &amp; Hers Health with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Hims & Hers Health, Inc. Class A Common Stock

HIMS

Check Out What Whales Are Doing With HIMS

<p>RBC Capital  analyst Conor McNamara   maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Outperform and lowers the price target from $247 to $128.</p>


ILMN

RBC Capital Maintains Outperform on Illumina, Lowers Price Target to $128

<p>Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) is making waves in the AI space with its new artificial intelligence model, <a href="https://qwenlm.github.io/blog/qwq-32b/">QwQ-32B</a>. Developed by its AI unit, Qwen, this model has 32 billion parameters and claims performance comparable to DeepSeek's R1 model which has 671 billion parameters. This is in line with China's broader push to support key industries such as <a href="https://www.benzinga.com/news/25/02/43903135/ais-19-9-trillion-impact-could-create-the-first-trillionaire-but-mark-cuban-says-it-wont-be-musk-or-bezos">AI</a>, humanoid robots and 6G.</p>
<h2 class="wp-block-heading">Alibaba's Big Bet on AI</h2>
<p>After the QwQ-32B announcement, Alibaba's Hong Kong shares <a href="https://economictimes.indiatimes.com/markets/stocks/news/alibaba-shares-soar-74-in-2025-amid-the-latest-ai-bet-deepseek-rivalry-china-stocks-turning-a-corner/articleshow/118778507.cms?from=mdr">surged over 8%</a> and this year is up nearly 70%. As of March 9, the company's market cap is around $345 billion, according to Companies MarketCap. Alibaba's AI strategy is gaining traction.</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/money/qnetic-2">This 12,000 RPM Spinning Battery With Over $100 Million In LOIs Could Be The Missing Link For Green Energy — Here&#8217;s Why Early Investors Are Flocking To Invest Before Funding Closes</a></strong></li>
<li><strong>BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks"><strong>One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</strong></a></strong></li>
</ul>
<p>According to <a href="https://qwenlm.github.io/blog/qwq-32b/">Qwen</a>, although QwQ-32B has fewer parameters than DeepSeek's R1, it excels in mathematical reasoning, coding and problem solving. This means operational cost savings and Alibaba is more competitive in the AI race. According to <a href="https://www.alibabacloud.com/blog/alibaba-cloud-teams-up-with-honor-zeekr-to-drive-ai-innovation-in-edge-devices_602046?spm=a2c65.11461447.0.0.39722486TOxjz4">Alibaba Cloud</a>, the company is also working with tech firms to put AI into consumer devices so its advancements can reach a broader audience.</p>
<p>Alibaba's top leaders have been meeting with Chinese government officials, including a meeting between President <strong>Xi Jinping</strong> and <strong>Jack Ma, </strong>Alibaba's co-founder. This level of engagement means strong government support for China's tech sector and its comeback.</p>
<p>Beijing's backing is a big reason for Alibaba's aggressive investment in AI. <a href="https://www.alibabacloud.com/blog/alibaba-to-invest-rmb380-billion-in-ai-and-cloud-infrastructure-over-next-three-years_602007">Alibaba Group announced</a> a plan to invest $53 billion for cloud computing and AI infrastructure. CEO <strong>Eddie Wu</strong> called AI a "once in a generation" opportunity that can replicate both intellectual and physical labor globally.</p>
<p><strong>Trending: Dogecoin millionaires are increasing –<a href="https://www.benzinga.com/money/dogecoin-millionaires"><strong> </strong><strong>investors with $1M+ in DOGE revealed!</strong></a></strong></p>
<p>Financially, Alibaba Cloud<strong> </strong>is reflecting this AI-first approach with 11% year-over-year revenue growth and AI related product revenue up triple digits for the sixth quarter in a row.</p>
<p>Alibaba is not alone in going all in on AI. According to <a href="https://www.digitaltrends.com/computing/amazon-to-spend-an-estimated-100-billion-ai-2025/">Digitaltrends</a>, Amazon Web Services is planning to spend around $100 billion next year, mostly on AI initiatives while Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) is expected to <a href="https://blogs.microsoft.com/on-the-issues/2025/01/03/the-golden-opportunity-for-american-ai/">spend around $80 billion</a> with a big chunk on AI development. But experts are concerned.</p>
<p>Despite QwQ-32B&#8217;s efficiency, <a href="https://www.knowledgegpt.com/post/ai-language-models-reasoning-flaws-revealed">researchers</a> wonder if smaller models can manage the intricacies of the actual world just as effectively as larger models. Small models may struggle with tasks that require extensive contextual understanding, which larger models do better.</p>
<p><strong><em>See Also: <a href="https://www.benzinga.com/money/gbr-savings-by-age"><strong><em>If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</em></strong></a></em></strong></p>
<p>Alibaba's QwQ-32B is a big deal in AI, but as competition heats up and concerns grow the question is how do we make sure AI serves technological progress and societal well-being.</p>
<p>The rapid development of AI without ethics is raising big concerns of unintended consequences, including decision making bias and job displacement. According to <a href="https://www.theguardian.com/us-news/2025/mar/04/trump-ai-labor-protections">The Guardian</a>, recent rollbacks of AI-related labor protections in the US has made workers more vulnerable to automation <a href="https://www.benzinga.com/startups/25/02/43679965/klarnas-ceo-says-ai-can-already-do-all-the-jobs-that-we-as-humans-do-and-hes-proving-it-by-shrinking-his-workforce-by-22">job</a> losses and deteriorating employment conditions.</p>
<p>Experts warn that without proper regulations, companies will prioritise efficiency over human labor, perpetuating economic inequality and embedding biases into AI systems.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong>The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks"><strong>See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</strong></a></strong></li>
<li><strong><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></strong></li>
</ul>


Personal Finance

BABA

MSFT

Jack Ma, Xi Jinping, And The $53B AI Bet—Alibaba's Comeback Signals A New Era For Chinese Big Tech

<p>Keurig Dr Pepper (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDP#NASDAQ">KDP</a>) has outperformed the market over the past 15 years by 1.12% on an annualized basis producing an average annual return of 12.08%. Currently, Keurig Dr Pepper has a market capitalization of $44.53 billion. </p>
<p><strong>Buying $100 In KDP:</strong> If an investor had bought $100 of KDP stock 15 years ago, it would be worth <strong>$553.35</strong> today based on a price of $32.82 for KDP at the time of writing.</p>
<h3>Keurig Dr Pepper's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741794311_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

<p><a href="https://www.marijuanamoment.net/nevada-senators-take-up-resolution-calling-on-congress-to-reschedule-psychedelics-and-streamline-research/#:~:text=The%20resolution%20goes%20through%20research,reflects%20the%20therapeutic%20value%2C%20low" title="https://www.marijuanamoment.net/nevada-senators-take-up-resolution-calling-on-congress-to-reschedule-psychedelics-and-streamline-research/#:~:text=The%20resolution%20goes%20through%20research,reflects%20the%20therapeutic%20value%2C%20low">https://www.marijuanamoment.net/nevada-senators-take-up-resolution-calling-on-congress-to-reschedule-psychedelics-and-streamline-research/#:~:text=The%20resolution%20goes%20through%20research,reflects%20the%20therapeutic%20value%2C%20low</a></p>


Biotech

Legal

General

ATAI

CMND

CMPS

CYBN

DRUG

MIRA

MNMD

'Nevada Senators Take Up Resolution Calling On Congress To Reschedule Psychedelics And Streamline Research' - Marijuana Moment

<p>RBC Capital  analyst Mike Dahl   maintains Ferguson Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) with a Outperform and lowers the price target from $211 to $189.</p>


FERG

RBC Capital Maintains Outperform on Ferguson Enterprises, Lowers Price Target to $189

<p>Barrington Research  analyst Alexander Paris   maintains SuRo Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSSS#NASDAQ">SSSS</a>) with a Outperform and maintains $8 price target.</p>


SSSS

Barrington Research Maintains Outperform on SuRo Capital, Maintains $8 Price Target

<p><a href="https://www.statnews.com/2025/03/12/telehealth-platforms-senators-crosshairs-over-relationship-with-eli-lilly-pfizer/#:~:text=The%20group%20of%20senators%20led,the%20ability%20to%20fill%20prescriptions" title="https://www.statnews.com/2025/03/12/telehealth-platforms-senators-crosshairs-over-relationship-with-eli-lilly-pfizer/#:~:text=The%20group%20of%20senators%20led,the%20ability%20to%20fill%20prescriptions">https://www.statnews.com/2025/03/12/telehealth-platforms-senators-crosshairs-over-relationship-with-eli-lilly-pfizer/#:~:text=The%20group%20of%20senators%20led,the%20ability%20to%20fill%20prescriptions</a></p>


'Telehealth Platforms In Senators' Crosshairs Over Relationship With Eli Lilly, Pfizer; In Letters, Lawmakers Question If Direct-To-Consumer Deals Could Influence Prescriptions' - STAT News

<p>Macquarie  analyst Tao Qiu   maintains Brookdale Senior Living (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKD#NYSE">BKD</a>) with a Outperform and maintains $8 price target.</p>


Macquarie Maintains Outperform on Brookdale Senior Living, Maintains $8 Price Target

<p>RBC Capital  analyst Irene Nattel   maintains Casey's General Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASY#NASDAQ">CASY</a>) with a Sector Perform and raises the price target from $430 to $438.</p>


CASY

RBC Capital Maintains Sector Perform on Casey's General Stores, Raises Price Target to $438

<p><a href="https://www.niaid.nih.gov/news-events/tecovirimat-safe-ineffective-treatment-clade-ii-mpox">https://www.niaid.nih.gov/news-events/tecovirimat-safe-ineffective-treatment-clade-ii-mpox</a></p>
<p>The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international clinical trial sponsored by the National Institutes of Health (NIH). The&nbsp;<a href="https://www.niaid.nih.gov/news-events/nih-study-finds-tecovirimat-was-safe-did-not-improve-mpox-resolution-or-pain">trial enrollment was stopped in late 2024</a> when an interim analysis showed that tecovirimat monotherapy was ineffective in the study population. Detailed results were presented at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco.</p>


SIGA

'Tecovirimat Is Safe But Ineffective As Treatment For Clade II Mpox' - NIH

<p>RBC Capital  analyst James McGarragle   reiterates CAE (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CAE#TSX">CAE</a>) with a Outperform and maintains C$43 price target.</p>


Reiteration

TSX:CAE

RBC Capital Reiterates Outperform on CAE, Maintains C$43 Price Target

<p>Macquarie  analyst Paul Golding   maintains Vail Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) with a Neutral and lowers the price target from $195 to $185.</p>


Macquarie Maintains Neutral on Vail Resorts, Lowers Price Target to $185

<p>RBC Capital  analyst James McGarragle   reiterates CAE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAE#NYSE">CAE</a>) with a Outperform and maintains $43 price target.</p>


Comments

EA Series Trust Strive 500 ETF

Noticias

Últimas noticias sobre EA Series Trust Strive 500 ETF (NYSE:STRV)

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL